Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer

被引：0
作者：
Mohamed Hebbar
Marc Ychou
Michel Ducreux
机构：
[1] Centre Hospitalo-Universitaire,Unité d’Oncologie Médicale
[2] Val d’Aurelle Anti-Cancer Centre,Department of Digestive Oncology
[3] Gustave-Roussy Institute,Department of Digestive Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2009年 / 135卷
关键词：
Colorectal cancer; Liver metastases; Irinotecan; UGT1A1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：749 / 752
页数：3
相关论文
共 50 条
  • [31] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
  • [32] Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver
    Baidoun, Firas
    Merjaneh, Zahi
    Nanah, Rama
    Saad, Anas M.
    Abdel-Rahman, Omar
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (13) : 935 - 951
  • [33] A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer
    Lubner, Sam J.
    LoConte, Noelle K.
    Holen, Kyle D.
    Schelman, William
    Thomas, James P.
    Jumonville, Alcee
    Eickhoff, Jens C.
    Seo, Songwon
    Mulkerin, Daniel L.
    CLINICAL COLORECTAL CANCER, 2010, 9 (03) : 157 - 161
  • [34] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [35] Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Goldberg, RM
    Gill, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (Suppl 1) : S57 - S64
  • [36] Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer
    Czejka, M.
    Kiss, A.
    Koessner, C.
    Terkola, R.
    Ettlinger, D.
    Schueller, J.
    ANTICANCER RESEARCH, 2011, 31 (10) : 3573 - 3578
  • [37] Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver
    Hernandez-Unzueta, Iera
    Benedicto, Aitor
    Olaso, Elvira
    Sanz, Eduardo
    Viera, Cristina
    Arteta, Beatriz
    Marquez, Joana
    ONCOLOGY LETTERS, 2017, 13 (06) : 4002 - 4012
  • [38] Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Richard M. Goldberg
    Sharlene Gill
    Cancer Chemotherapy and Pharmacology, 2004, 54 : S57 - S64
  • [39] aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Fujita, Yoshihiko
    Taguri, Masataka
    Yamazaki, Kentaro
    Tsurutani, Junji
    Sakai, Kazuko
    Tsushima, Takahiro
    Nagase, Michitaka
    Tamagawa, Hiroshi
    Ueda, Shinya
    Tamura, Takao
    Tsuji, Yasushi
    Murata, Kohei
    Taira, Koichi
    Denda, Tadamichi
    Moriwaki, Toshikazu
    Funai, Sadao
    Nakajima, Takako Eguchi
    Muro, Kei
    Tsuji, Akihito
    Yoshida, Motoki
    Suyama, Koichi
    Kurimoto, Takuya
    Sugimoto, Naotoshi
    Baba, Eishi
    Seki, Nobuhiko
    Sato, Mikio
    Shimura, Takaya
    Boku, Narikazu
    Hyodo, Ichinosuke
    Yamanaka, Takeharu
    Nishio, Kazuto
    ONCOLOGIST, 2019, 24 (03) : 327 - 337
  • [40] A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
    Allegrini, G.
    Falcone, A.
    Fioravanti, A.
    Barletta, M. T.
    Orlandi, P.
    Loupakis, F.
    Cerri, E.
    Masi, G.
    Di Paolo, A.
    Kerbel, R. S.
    Danesi, R.
    Del Tacca, M.
    Bocci, G.
    BRITISH JOURNAL OF CANCER, 2008, 98 (08) : 1312 - 1319
12345